MHRA and NICE Open Evidence Call on Digital Mental Health Resources

The survey runs until 26 February 2027 and will assess how Phase 1 resources have been received and used.

The Medicines and Healthcare products Regulatory Agency (MHRA) and the National Institute for Health and Care Excellence (NICE) have launched a call for evidence to evaluate the impact of resources developed under the Wellcome-funded Digital Mental Health Technologies (DMHT) programme. The survey opened on 5 November 2026 and will remain open until 26 February 2027.

The programme is seeking feedback from developers and manufacturers of digital mental health technologies, healthcare professionals, researchers, policymakers, regulators, people with lived experience of mental health conditions, carers and members of the public.

According to the MHRA and NICE, the survey is part of the programme's Phase 1 evaluation. It aims to assess how the resources have been received and used across the sector. The organisations are particularly interested in whether the materials have influenced users' knowledge, confidence, decision-making and professional practice.

Purpose of the resources

The resources were developed to support the safe development, regulation, evaluation and adoption of digital mental health technologies, including mental health apps and other digital tools. Findings from the survey will help determine whether the Phase 1 outputs achieved their intended objectives and will inform the future direction of Phase 2 of the DMHT programme.

Stakeholders are encouraged to take part whether they have engaged extensively, minimally or not at all with the existing resources. The MHRA and NICE say the feedback will help identify strengths, highlight areas for improvement and shape future work intended to improve the safety and effectiveness of digital mental health technologies.

SM

Sonia Marchetti

Sonia Marchetti covers home blood pressure monitors, digital thermometers, and pulse oximeters as a home health devices analyst focused on product selection and use boundaries. Her evidence framework examines cuff fit, measurement repeatability, thermometer placement, battery behavior, and the intended scope of ISO 81060-2 for automated blood pressure validation without assuming any device has passed it. She helps private label managers, pharmacy buyers, and quality teams compare sample evidence, labeling claims, and maintenance needs while leaving individual readings and clinical decisions to qualified care professionals.